MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. (AQST)

|||

Cash Flow Overview

Free Cash flow
-$9,653K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of long-t...
    • Loss on extinguishment of debt
    • Share-based compensation
    • Others
Negative Cash Flow Breakdown
    • Repayment of debt principal - 13...
    • Net loss
    • Premium paid to retire debt - 13...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-22,864
-8,057
-31,860
-15,446
Depreciation, amortization, and impairment
136
113
130
139
Gain on contract termination
-
-
0
0
Share-based compensation
2,895
2,318
1,376
2,777
Loss on extinguishment of debt
-11,683
-
-
-
Issuance of warrants
-
916
-
-
Issuance of warrants under the purchase agreement
916
-
-
-
Amortization of debt issuance costs and discounts
1,767
2,286
2,749
2,748
Other, net
-43
-6
-1
-11
Trade and other receivables, net
2,459
-10,896
5,959
-63
Inventories
-706
1,896
-1,714
-241
Prepaid expenses and other assets
-2,136
340
685
1,721
Accounts payable
-3,427
-17,973
19,247
-1,306
Accrued expenses and other liabilities
216
-2,803
5,090
118
Deferred revenue
-273
-272
-272
-273
Net cash used for operating activities
-9,441
-14,806
-8,469
-12,649
Capital expenditures
212
52
85
235
Net cash used for investing activities
-212
-52
-85
-235
Proceeds from common stock issued under public equity offering-atm, net
-79
4,759
21,194
-
Proceeds from common stock issued under public equity offering-At The Market Offering
-
-
-
-9
Proceeds from common stock issued under public equity offering, net
-
-
79,460
-
Proceeds from issuance of long-term debt under the credit agreement
54,337
-
-
-
Proceeds from common stock issued under public equity offering-Public Equity Offering
-
-
-
79,728
Proceeds from exercise of warrants, net
-
-
0
1,430
Proceeds from issuance of warrants under the credit agreement
663
-
-
-
Proceeds from shares issued under employee stock purchase plan
70
-
60
0
Proceeds from exercise of stock options, net
26
1
924
339
Repayment of debt principal - 13.5 notes
44,992
8
26
-
Debt exit fee paid - 13.5 notes
2,000
-
-
-
Premium paid to retire debt - 13.5 notes
3,887
-
-
-
Payments for financing costs
3,449
-
-
7
Payments for lease liabilities
18
-
-
-
Payments for royalty obligations
0
0
0
11
Payments for taxes on share-based compensation, net
3,241
329
18
70
Net cash provided by financing activities
-2,591
4,423
660
81,411
Net decrease in cash and cash equivalents
-12,244
-10,435
-7,894
68,527
Cash and cash equivalents at beginning of period
110,734
121,169
129,063
71,546
Cash and cash equivalents at end of period
98,490
110,734
121,169
129,063
Cash payments for interest
2,269
-
-
-
Non-cash investing activities capital expenditures in accounts payable
43
-
-
-
Non-cash financing activities term loan facility costs in accounts payable
461
-
-
-
Interest rate (as a percent)
0
-
-
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net decrease in cashand cash...-$12,244K (-11.21%↓ Y/Y)Loss onextinguishment of debt-$11,683K Share-based compensation$2,895K (-16.59%↓ Y/Y)Prepaid expenses andother assets-$2,136K (31.19%↑ Y/Y)Amortization of debt issuancecosts and discounts$1,767K (-67.86%↓ Y/Y)Issuance of warrantsunder the purchase...$916K Inventories-$706K (-133.93%↓ Y/Y)Accrued expenses andother liabilities$216K (109.93%↑ Y/Y)Depreciation, amortization,and impairment$136K (-51.25%↓ Y/Y)Other, net-$43K (-490.91%↓ Y/Y)Proceeds from issuance oflong-term debt under the...$54,337K Proceeds from issuance ofwarrants under the credit...$663K Proceeds from sharesissued under employee...$70K (40.00%↑ Y/Y)Proceeds from exercise ofstock options, net$26K (271.43%↑ Y/Y)Net cash used foroperating activities-$9,441K (69.85%↑ Y/Y)Net cash provided byfinancing activities-$2,591K (-112.61%↓ Y/Y)Net cash used forinvesting activities-$212K (12.40%↑ Y/Y)Canceled cashflow$20,498K Canceled cashflow$55,096K Net loss-$22,864K (37.32%↑ Y/Y)Repayment of debtprincipal - 13.5 notes$44,992K Capital expenditures$212K (-12.40%↓ Y/Y)Accounts payable-$3,427K (-316.62%↓ Y/Y)Trade and otherreceivables, net$2,459K (-45.06%↓ Y/Y)something is missing-$916K Deferred revenue-$273K (-950.00%↓ Y/Y)Premium paid to retiredebt - 13.5 notes$3,887K Payments for financingcosts$3,449K (24535.71%↑ Y/Y)Payments for taxes onshare-based compensation,...$3,241K (348.89%↑ Y/Y)Debt exit fee paid -13.5 notes$2,000K Proceeds from commonstock issued under...-$79K Payments for leaseliabilities$18K